GIC-1001

gicare Pharma Inc. · Phase 2 active Small molecule

At a glance

Generic name	GIC-1001
Also known as	trimebutine 3-thiocarbamoylbenzenesulfonate, TB-905-02
Sponsor	gicare Pharma Inc.
Modality	Small molecule
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

A Phase 2a, Proof-of-Concept Study of GIC-1001 in the Management of Visceral Pain During Sedation-Free, Full Colonoscopy (PHASE2)
Study on Analgesia of GIC-1001 & GIC-1002 on Visceral Pain, Rectal Sensory Threshold Using the Barostat Method (PHASE1)
A Clinical Phase I Study on GIC-1001 in Healthy Volunteers (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

GIC-1001 CI brief — competitive landscape report
GIC-1001 updates RSS · CI watch RSS
gicare Pharma Inc. portfolio CI